Qiagen
Qiagen's revenue rose 5.7% to $2.1 billion in fiscal 2025. Its operating margin was 22.3%, up from 4.9% a year earlier. Free cash flow was $453 million, down 10.5%. It paid out $334 million in dividends and buybacks, 74% of free cash flow. The diluted share count fell 2.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
From fiscal 2016 to 2025, earnings per share grew 21.3% a year and net income 20.3% a year, as buybacks cut the share count by 8%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,065 | 1,418 | 1,058 | 1,153 | 1,099 |
| Debt incl. finance leases | 1,942 | 1,861 | 1,510 | 1,392 | 1,654 |
| Net debt (negative means net cash) | 876 | 443 | 452 | 238 | 556 |
| Net debt to EBITDA | 1.0x | 0.6x | 0.7x | 0.8x | 0.8x |
| Debt to equity | 0.6x | 0.5x | 0.4x | 0.4x | 0.4x |
| Interest coverage | 11.6x | 9.1x | 7.7x | 2.2x | 14.0x |
| Current ratio | 1.4x | 2.5x | 2.0x | 1.9x | 3.9x |
| Quick ratio | 1.2x | 2.1x | 1.6x | 1.6x | 3.3x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 6 of 9 | 8 of 9 |
| Rule of 40 | 7.5% | 26.2% | 27.3% |
| Altman Z'' | 4.64 | 4.34 | 5.06 |
| Accruals ratio | −1.9% | −10.0% | −3.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Pass | Pass |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 4 of 9 | 6 of 9 | 8 of 9 |
Compare
Put Qiagen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Qiagen | FY25 | 5.7% | 22.3% | 21.7% | 9.9% | 0.8x | 8 | |
| Medpace | FY25 | 20.0% | 21.1% | 26.9% | — | −0.9x | 4 | Compare |
| Bio-Rad Laboratories | FY25 | 0.7% | 1.8% | 14.5% | 0.5% | −1.6x | 5 | Compare |
| Waters | FY25 | 7.0% | 25.4% | 17.1% | 21.0% | 0.8x | 6 | Compare |
| Bio-Techne | FY26 | −0.4% | 20.7% | 21.7% | 9.2% | −0.2x | 9 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,338 | 1,418 | 1,502 | 1,526 | 1,870 | 2,252 | 2,142 | 1,965 | 1,978 | 2,090 |
| Revenue growth | 4.5% | 6.0% | 6.0% | 1.6% | 22.5% | 20.4% | −4.9% | −8.2% | 0.7% | 5.7% |
| Gross profit | 845 | 923 | 1,001 | 1,005 | 1,233 | 1,451 | 1,385 | 1,234 | 967 | 1,300 |
| Research and development | 150 | 154 | 162 | 157 | 149 | 190 | 190 | 198 | 194 | 188 |
| Operating income | 99 | 153 | 267 | −26 | 386 | 630 | 532 | 410 | 98 | 466 |
| Net income | 80 | 40 | 190 | −42 | 359 | 513 | 423 | 341 | 84 | 425 |
| Diluted EPS (US$) | 0.34 | 0.17 | 0.82 | −0.18 | 1.53 | 2.21 | 1.84 | 1.48 | 0.37 | 1.94 |
| Diluted shares (millions) | 239 | 233 | 234 | 227 | 234 | 232 | 230 | 231 | 225 | 219 |
| Cash flow | ||||||||||
| Cash from operations | 342 | 287 | 360 | 331 | 458 | 639 | 715 | 460 | 674 | 654 |
| Capital expenditure | 74 | 90 | 110 | 118 | 133 | 190 | 129 | 150 | 167 | 201 |
| Free cash flow | 267 | 197 | 250 | 213 | 325 | 449 | 586 | 310 | 506 | 453 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54 |
| Share buybacks | 0 | 61 | 105 | 74 | 64 | 100 | 0 | 0 | 292 | 280 |
| Acquisitions | 90 | 50 | 173 | 68 | 240 | 0 | 64 | 150 | 0 | 291 |
| Stock-based compensation | 28 | 34 | 40 | 66 | 41 | 38 | 50 | 47 | 44 | 50 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 532 | 1,017 | 1,394 | 753 | 715 | 1,065 | 1,418 | 1,058 | 1,153 | 1,099 |
| Debt incl. finance leases | 1,067 | 1,758 | 2,174 | 1,706 | 1,923 | 1,942 | 1,861 | 1,510 | 1,392 | 1,654 |
| Total assets | 4,308 | 5,038 | 5,748 | 5,236 | 5,870 | 6,147 | 6,288 | 6,115 | 5,690 | 6,281 |
| Total liabilities | 1,701 | 2,498 | 3,113 | 2,699 | 3,072 | 3,050 | 2,821 | 2,307 | 2,122 | 2,503 |
| Shareholders' equity | 2,607 | 2,541 | 2,635 | 2,537 | 2,798 | 3,096 | 3,467 | 3,808 | 3,567 | 3,778 |
| Margins and ratios | ||||||||||
| Gross margin | 63.1% | 65.1% | 66.7% | 65.9% | 65.9% | 64.4% | 64.7% | 62.8% | 48.9% | 62.2% |
| Operating margin | 7.4% | 10.8% | 17.8% | −1.7% | 20.7% | 28.0% | 24.8% | 20.9% | 4.9% | 22.3% |
| Net margin | 6.0% | 2.9% | 12.7% | −2.7% | 19.2% | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| Free cash flow margin | 20.0% | 13.9% | 16.6% | 13.9% | 17.4% | 19.9% | 27.4% | 15.8% | 25.6% | 21.7% |
| Rule of 40 (growth + FCF margin) | 24.4% | 19.8% | 22.6% | 15.6% | 39.9% | 40.3% | 22.5% | 7.5% | 26.2% | 27.3% |
| Return on capital | 3.1% | 2.4% | 6.7% | −0.6% | 8.4% | 12.9% | 11.1% | 8.0% | 1.7% | 9.9% |
| Return on equity | 3.1% | 1.6% | 7.4% | −1.6% | 13.5% | 17.4% | 12.9% | 9.4% | 2.3% | 11.6% |
| Return on assets | 1.9% | 0.9% | 3.5% | −0.8% | 6.5% | 8.5% | 6.8% | 5.5% | 1.4% | 7.1% |
| Net debt to EBITDA | 1.7x | 2.0x | 1.6x | 4.6x | 2.0x | 1.0x | 0.6x | 0.7x | 0.8x | 0.8x |